India, June 11 -- Enliven Therapeutics, Inc. (ELVN), reported on Thursday an updated positive result from the Phase 1 ENABLE trial of ELVN-001 in patients who were previously treated for Chronic Myeloid Leukemia (CML).
Company Profile
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule precision oncology therapies. Its pipeline includes targeted kinase inhibitors designed to address unmet needs in various cancers.
Chronic Myeloid Leukemia (CML)
Chronic myeloid leukemia is a type of bone marrow cancer characterized by an increased number of white blood cells in the blood. Chromosome 9 and Chromosome 22 combine to form the breakpoint cluster region-Abelson "BCR::ABL" gene, which instruct...